@article{a9b1d819bd1e43978bc893a94592c168,
title = "Is grand multiparity associated with an increased risk of dysglycaemia?",
abstract = "Aims/hypothesis: We sought to determine the risk of diabetes and IGT/IFG with grand multiparity. Subjects, materials and methods: Women, aged ≥25 years, from the Australian Diabetes, Obesity and Lifestyle Study and the Crossroads Undiagnosed Disease Study (a rural study in Victoria, Australia), participated in a household census (response 67 and 70%, respectively), subsequently attending a biomedical examination that included an oral glucose tolerance test (58% [6198] and 69% [819]). Results: After adjusting for age, obesity and socio-economic status, diabetes, but not IGT/IFG, was less common among women with a parity of 1 to 2 (odds ratio [OR]=0.64 [0.48-0.84]) and 3 to 4 (OR=0.72 [0.53-0.96]) than in grand multiparous women. This relationship was unrelated to past hysterectomy, use of the oral contraceptive pill or menopausal status. Conclusions/interpretation: Grand multiparity is associated with an increased risk of diabetes but not of IGT/IFG. We postulate that parity accelerates transition from IGT/IFG to diabetes, more than it does transition from normal glucose tolerance to IGT/IFG.",
keywords = "Diabetes, Hysterectomy, Menopause, Oral contraceptive pill, Parity",
author = "D. Simmons and J. Shaw and A. McKenzie and S. Eaton and Cameron, {A. J.} and P. Zimmet",
note = "Funding Information: Acknowledgements We thank the Crossroads team for their work and the local communities for their support. The Crossroads Undiagnosed Disease Study was funded by the International Diabetes Institute and the University of Melbourne. The Department of Rural Health is funded under the Department of Health and Ageing Rural Health programme. We thank G. Joshy for statistical assistance. The AusDiab team are grateful to the following for their support of the study: the Commonwealth Dept of Health and Aged Care, Abbott Australasia, Alphapharm, Aventis Pharmaceutical, AstraZeneca, Bristol-Myers Squibb Pharmaceuticals, Eli Lilly (Aust), GlaxoSmithKline, Janssen–Cilag (Aust), Merck Lipha, Merck Sharp & Dohme (Aust), Novartis Pharmaceutical (Aust), Novo Nordisk Pharmaceutical, Pharmacia and Upjohn, Pfizer, Roche Diagnostics, Sanofi Synthelabo (Aust), Servier Laboratories (Aust), BioRad Laboratories, HITECH Pathology, the Australian Kidney Foundation, Diabetes Australia, Diabetes Australia (Northern Territory), Queensland Health, South Australian Department of Human Services, Tasmanian Department of Health and Human Services, Territory Health Services, Victorian Department of Human Services and Health Department of Western Australia. We are also enormously grateful to A. Allman, M. Dalton, D. Dunstan, A. Meehan, C. Reid, A. Stewart, R. Tapp and F.Wilson for their invaluable contribution to the field activities of AusDiab.",
year = "2006",
month = jul,
doi = "10.1007/s00125-006-0276-6",
language = "English",
volume = "49",
pages = "1522--1527",
journal = "Diabetologia",
issn = "0012-186X",
publisher = "Springer Science and Business Media Deutschland GmbH",
number = "7",
}